Niagen Bioscience(NASDAQ) NAGE

Market Cap$235.75M

Since IPO (2008)-74%

5 Year-66%

1 Year-68%

1 Month-15%

$2.96

-14.84%

-0.51Today

After hours$2.96+$0.00 (+0.17%)

Niagen Bioscience last closing stock price
Metric	Price	Date
Last close	USD 2.96	2026-08-05

Niagen Bioscience stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-8.07%	USD 3.22	2026-07-29
1 month	-15.43%	USD 3.50	2026-07-06
3 month	-29.36%	USD 4.19	2026-05-07
Year to date	-53.46%	USD 6.36	2025-12-31
1 year	-67.69%	USD 9.16	2025-08-05
3 year	+80.49%	USD 1.64	2023-08-04
5 year	-66.13%	USD 8.74	2021-08-06
Since inception	-73.69%	USD 11.25	2008-06-24

Niagen Bioscience Financials at a Glance

Market Cap

$235.75M

Revenue (TTM)

$130.42M

Net Income (TTM)

$18.64M

EPS (TTM)

$0.22

P/E Ratio

13.56

Dividend

$0.00

Beta (Volatility)

1.50 (High)

Dividend

$0.00

Beta (Volatility)

1.50 (High)

Price

$2.96

Volume

1,826,335

Open

$3.11

Price

$2.96

Volume

1,826,335

Open

$3.11

Previous Close

$2.96

Daily Range

$2.87 - $3.21

52-Week Range

$2.87 - $11.29

Estimated Earnings Date

Nov 3, 2026

Dividend

$0.00

Beta (Volatility)

1.50 (High)

Price

$2.96

Volume

1,826,335

Open

$3.11

Previous Close

$2.96

Daily Range

$2.87 - $3.21

52-Week Range

$2.87 - $11.29

Estimated Earnings Date

Nov 3, 2026

NAGE News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Niagen Bioscience

Niagen Bioscience helps people age healthily through cellular research. Its main products boost a coenzyme that supports body cells. These offerings serve health-conscious consumers and medical researchers.

What the Company Makes

Consumer Products: Finished dietary supplements and skincare sold under the Tru Niagen brand; generated $22.4 million in net sales in Q1 2026.
Ingredients: Raw materials like food-grade and pharmaceutical-grade Niagen supplied to other manufacturers; contributed $8.6 million in net sales in Q1 2026.
Pharmaceuticals: Research and development of nicotinamide adenine dinucleotide (NAD+) precursors for rare diseases; currently generates no revenue.

Strategic Moves and Partnerships

Sold the analytical reference standards business in February 2026 to a third party for $6 million.
Maintains an exclusive manufacturing agreement for nicotinamide riboside chloride with W.R. Grace & Co through 2029.
Collaborates with Societe des Produits Nestle SA to supply ingredients for medical and nutritional products.
Acquired patent rights from The Queen's University of Belfast (QUB) in December 2025 to expand its technology portfolio.

The Science of Aging

The company protects its business with a global portfolio of patents covering nicotinamide riboside, a key regulator of metabolism. It uses a specialized external research program to validate its technologies through clinical studies at major universities.

A Look at the Numbers

Revenue reached $31.5 million in Q1 2026, up 3.3% from $30.5 million in Q1 2025.
Net income hit $6.3 million in Q1 2026, up 24.8% from $5.1 million in Q1 2025.
Operating income was $1.6 million in Q1 2026, down 67% from $4.8 million in Q1 2025.
Free cash flow reached negative $1.3 million in Q1 2026, worsened from $7.9 million in Q1 2025.
Cash and cash equivalents totaled $66.5 million as of March 31, 2026.

The Evolution of Niagen

Niagen has transitioned from a laboratory services provider into a focused consumer health and ingredient technology company. Its growth now depends on commercializing cellular science through global retail and pharmaceutical partnerships.

AI Generated • May 12, 2026

Industry

Personal Products

Sector

Consumer Staples

Employees

117

CEO

Robert N. Fried, MBA

Website

www.niagenbioscience.com

Headquarters

Los Angeles, CA 90024, US

NAGE Financials

Key Financial Metrics (TTM)

Gross Margin

64.28%

Operating Margin

8.51%

Net Income Margin

14.29%

Return on Equity

25.38%

Return on Capital

18.02%

Return on Assets

16.30%

Earnings Yield

7.37%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$235.75M

Shares Outstanding

79.64M

Volume

1.83M

Avg. Volume

878.80K

Financials (TTM)

Gross Profit

$83.83M

Operating Income

$11.10M

EBITDA

$21.40M

Operating Cash Flow

$4.43M

Capital Expenditure

-$321.00K

Free Cash Flow

$4.11M

Cash & ST Invst.

$66.55M

Total Debt

$2.58M

Niagen Bioscience Performance Analysis

Niagen Bioscience annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 72,050,000	6.8%
2023	2023-12-31	USD 83,570,000	16.0%
2024	2024-12-31	USD 99,597,000	19.2%
2025	2025-12-31	USD 129,423,000	29.9%

Niagen Bioscience sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	2.1%
Q3	2025-09-30	9.2%
Q4	2025-12-31	-0.4%
Q1	2026-03-31	-7.0%

Niagen Bioscience annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -0.24	-41.3%
2023	2023-12-31	USD -0.07	-72.2%
2024	2024-12-31	USD 0.11	N/A
2025	2025-12-31	USD 0.20	85.9%

Niagen Bioscience sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-31.3%
Q3	2025-09-30	26.3%
Q4	2025-12-31	-7.4%
Q1	2026-03-31	52.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$31.47M

+3.3%

Gross Profit

$19.98M

+3.3%

Gross Margin

63.47%

N/A

Market Cap

$235.75M

N/A

Market Cap/Employee

$2.01M

N/A

Employees

117

N/A

Net Income

$6.32M

+24.8%

EBITDA

$7.03M

+25.5%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$66.55M

+20.0%

Total Debt

$2.58M

-26.9%

Accounts Receivable

$13.07M

+85.3%

Inventory

$24.02M

+114.7%

Long Term Debt

$1.54M

-40.1%

Short Term Debt

$1.03M

+8.9%

Return on Assets

16.30%

N/A

Return on Invested Capital

12.13%

N/A

Free Cash Flow

-$1.26M

-116.0%

Operating Cash Flow

-$1.19M

-115.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

KROSKeros Therapeutics, Inc.

KROSKeros Therapeutics, Inc.$10.00-2.49%

AKBAAkebia Therapeutics, Inc.

AKBAAkebia Therapeutics, Inc.$1.29-2.27%

PRTAProthena Corporation plc

PRTAProthena Corporation plc$8.49+0.00%

RGNXREGENXBIO Inc.

RGNXREGENXBIO Inc.$10.50+1.94%

ZVRAZevra Therapeutics, Inc.

ZVRAZevra Therapeutics, Inc.$10.53+0.10%

RIGLRigel Pharmaceuticals, Inc.

RIGLRigel Pharmaceuticals, Inc.$40.48+4.60%

VTYXVentyx Biosciences, Inc.

VTYXVentyx Biosciences, Inc.$14.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$108.27-0.14%

NVDANvidia

NVDANvidia$219.22+0.03%

ONDSOndas

ONDSOndas$8.87+0.00%

PATHUiPath

PATHUiPath$13.82-0.02%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.77-0.04%

INTCIntel

INTCIntel$101.06+0.00%

SNAPSnap

SNAPSnap$5.33-0.08%

Questions About NAGE

What is the current price of Niagen Bioscience?

Niagen Bioscience is trading at $2.96 per share.

What is the 52-week range for Niagen Bioscience?

Over the past 52 weeks, Niagen Bioscience has traded between $2.87 and $11.29.

How much debt does Niagen Bioscience have?

As of the most recent reporting period, Niagen Bioscience reported total debt of $2.58M.

How much cash does Niagen Bioscience have on hand?

Niagen Bioscience reported $66.55M in cash and cash equivalents in its most recent financial results.

What is Niagen Bioscience’s dividend yield?

Niagen Bioscience does not currently have a dividend yield.

Niagen Bioscience(NASDAQ) NAGE

Niagen Bioscience Financials at a Glance

NAGE News

Why ChromaDex Stock Is Sinking Today

Why ChromaDex Stock Is Jumping Today

Why ChromaDex Trounced the Market on Tuesday

Why ChromaDex Stock Blasted Almost 30% Higher Today Before Falling Into the Red

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Niagen Bioscience

What the Company Makes

Strategic Moves and Partnerships

The Science of Aging

A Look at the Numbers

The Evolution of Niagen

NAGE Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Niagen Bioscience Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About NAGE

What is the current price of Niagen Bioscience?

What is the 52-week range for Niagen Bioscience?

How much debt does Niagen Bioscience have?

How much cash does Niagen Bioscience have on hand?

What is Niagen Bioscience’s dividend yield?

Premium Investing Services